Immune Parameters of Korean Patients with Psoriasis Treated with Low-Dose Cyclosporine

참고문헌 (10)

1. Wicker LS, "Suppression of B cell activation by cyclosporin A, FK506 and rapamycin", Eur J Immunol, 20, pp.2277~2283 (1990)
2. Morteau O, "Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo", PLoS One, 5, pp.e13294~ (2010)
3. Amor KT, "The use of cyclosporine in dermatology: part I", J Am Acad Dermatol, 63, pp.925~946 (2010)
4. Cerman AA, "Serum leptin levels, skin leptin and leptin receptor expression in psoriasis", Br J Dermatol, 159, pp.820~826 (2008)
5. Sandra Swimberghe, "Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis(the Practice Study)", Annals of Dermatology, 25(1), pp.28~35 (2013), 대한피부과학회
6. Giese T, "Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A", Transplantation, 77, pp.339~344 (2004)
7. Brandt C, "Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis", Allergy, 64, pp.1588~1596 (2009)
8. Miroux C, "Inhibitory effects of cyclosporine on human regulatory T cells in vitro", Transplant Proc, 41, pp.3371~3374 (2009)
9. Takashima A, "Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment", J Invest Dermatol, 96, pp.376~382 (1991)
10. Wang H, "The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations", Blood, 110, pp.1530~1539 (2007)

관련 논문AI추천